(19)
(11) EP 3 156 069 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.10.2020 Bulletin 2020/43

(45) Mention of the grant of the patent:
05.08.2020 Bulletin 2020/32

(21) Application number: 16184921.1

(22) Date of filing: 19.06.2009
(51) International Patent Classification (IPC): 
A61K 39/12(2006.01)
A61P 35/00(2006.01)
A61K 39/395(2006.01)
 A61K 48/00(2006.01)
A61K 31/7105(2006.01)

(54)

COMPOSITIONS, METHODS, AND KITS FOR ELICITING AN IMMUNE RESPONSE

ZUSAMMENSETZUNGEN, VERFAHREN UND KITS ZUR AUSLÖSUNG EINER IMMUNREAKTION

COMPOSITIONS, PROCÉDÉS ET KITS PERMETTANT DE PROVOQUER UNE RÉPONSE IMMUNITAIRE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30) Priority: 20.06.2008 US 74582 P

(43) Date of publication of application:
19.04.2017 Bulletin 2017/16

(60) Divisional application:
20181935.6

(62) Application number of the earlier application in accordance with Art. 76 EPC:
09767844.5 / 2303319

(73) Proprietor: Duke University
Durham, NC 27705 (US)

(72) Inventors:
  • Sampson, John H.
    Durham, NC 27710 (US)
  • Mitchell, Duane A.
    Durham, NC 27710 (US)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
US-A1- 2003 118 602
   
  • MITCHELL DUANE A ET AL: "RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma", MOLECULAR THERAPY, vol. 17, no. Suppl. 1, May 2009 (2009-05), page S93, XP008154924, & 12TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE THERAPY; SAN DIEGO, CA, USA; MAY 27 -30, 2009 ISSN: 1525-0016
  • VAN DEN BOSCH, G.A. ET AL: "Ex vivo induction of viral antigen-specific CD8(+) T cell responses using mRNA -electroporated CD40-activated B cells", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 139, no. 3, 1 March 2005 (2005-03-01) , pages 458-467, XP008154937,
  • CARLSSON BJORN ET AL: "Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 121, no. 3, May 2003 (2003-05), pages 428-438, XP002682013, ISSN: 0007-1048
  • GRIGOLEIT ULRICH ET AL: "Dendritic cell vaccination induces HCMV specific T-Cell responses in allogeneic stem cell recipients.", BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11), page 143A, XP008154940, & 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005 ISSN: 0006-4971
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).